98%
921
2 minutes
20
Background: Early recurrences of atrial tachyarrhythmias (ERATs) after pulmonary vein isolation (PVI) are common. While many correlate to late recurrences (LRs), some do not. The impact of ERATs timing is difficult to assess with noninvasive Holter monitoring because of undersampling. The recommended duration of the blanking period (BP) was recently shortened from 90 days to 8 weeks.
Objective: The purpose of this study was to evaluate the impact of ERATs timing after PVI and the effect of a shorter BP by using implantable cardiac monitors for continuous rhythm monitoring.
Methods: This is a prespecified substudy of the Comparison of the POLARx and the Arctic Front cryoballoon for pulmonary vein isolation in patients with symptomatic paroxysmal atrial fibrillation (COMPARE-CRYO) study, which enrolled patients with paroxysmal atrial fibrillation undergoing cryoballoon ablation. All patients underwent implantable cardiac monitor implantation, and the BP was 90 days.
Results: A total of 5285 ERATs episodes occurred in 117 of 201 patients (58%). Freedom from LR was 82% vs 37% in patients without vs with ERATs (P<.001). When patients were classified according to their last episode of ERATs occurring between days 0 and 30, between days 31 and 60, and between days 61 and 90, freedom from LR was 60%, 56%, and 11%, respectively (P<.001). Seven of 201 patients (3.4%) had AF recurrence in the third month after ablation, but not between days 91 and 365, which reclassifies them from ablation success to ablation failure with the shortened 8-week BP.
Conclusion: ERATs after PVI is common. The presence of ERATs in the third month after PVI was highly predictive of ablation failure, supporting the shortening of the BP to 8 weeks; however, the shorter BP reclassifies only 7 (3.4%) of patients to ablation failure instead of ablation success.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hrthm.2024.12.013 | DOI Listing |
J Cardiovasc Electrophysiol
September 2025
Department of Cardiology, Beijing Anzhen Hospital, National Clinical Research Center for Cardiovascular Diseases, Capital Medical University, Beijing, China.
Aims: The impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on atrial fibrillation (AF) recurrence after catheter ablation is still inconclusive. Besides, their efficacy on AF recurrence stratified by metabolic syndrome (MetS) status remains unknown.
Methods: Patients with AF undergoing initial catheter ablation between January 2017 and December 2023 from the China-AF Registry were included.
Europace
September 2025
Baptist Health, Louisville, KY, United States.
JACC Clin Electrophysiol
September 2025
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address:
Background: The performance of cryoballoon (CB) ablation compared with radiofrequency (RF) ablation has been demonstrated in patients with paroxysmal atrial fibrillation (AF). However, the role of CB ablation in patients with persistent AF has not been well established. Furthermore, the efficacy of additional posterior wall isolation following CB pulmonary vein (PV) isolation remains controversial.
View Article and Find Full Text PDFJAMA Netw Open
August 2025
Section of Cardiac Electrophysiology, Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia.
Importance: Atrial fibrillation (AF) ablation aims to eliminate all AF triggers. Non-pulmonary vein (PV) triggers are observed in up to 10% of patients referred for a first AF ablation procedure. However, there are limited data on sex-specific differences in non-PV triggers.
View Article and Find Full Text PDFEuropace
August 2025
Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
Aims: To investigate the relationship between continuously monitored atrial fibrillation (AF) burden after cryoballoon ablation (CBA) and improvements in AF-related symptoms, quality of life (QoL), and AF-related healthcare resource utilization (HCRU) in early persistent AF.
Methods And Results: This secondary analysis of the multicentre COOL-PER trial included patients with early persistent AF who underwent CBA and continuous monitoring via an implantable loop recorder. Post-CBA AF burden was defined as the percentage of time in AF between 9- and 12-month after CBA, categorized as <0.